請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49137完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 翁啟惠(Chi-Huey Wong),吳宗益(Chung-Yi Wu) | |
| dc.contributor.author | Tzu-En Tseng | en |
| dc.contributor.author | 曾子恩 | zh_TW |
| dc.date.accessioned | 2021-06-15T11:17:04Z | - |
| dc.date.available | 2019-08-26 | |
| dc.date.copyright | 2016-08-26 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-08-19 | |
| dc.identifier.citation | (1) Zhang, S.;Zhang, H. S.; Reuter, V. E.; Slovin, S. F.; Scher, H. I.; Livingston, P. O. Clin. Cancer Res. 1998, 4, 295–306.
(2) Danishefsky, S. J.; Allen, J. R. Angew. Chem. Int. Ed. 2000, 39, 836–863. (3) Hakomori, S. Adv. Cancer Res. 1989, 52, 257. (4) Kuryashow, V.; Ragupathi, G.; Kim, I. J.; Breimer, M. E.; Danishefsky, S. J.; Livingston, P. O.; Lloyd, K. O. Glycoconjugate J. 1998, 15, 243–249. (5) Astronomo, R. D.; Burton, D. R. Nat. Rev. Drug. Disc. 2010, 9, 308–324. (6) Zhang, S.; Zhang, H. S.; Cordon-Cardo, C.; Reuter, V. E.; Singhal, A. K.; Lloyd, K. O.; Livingston, P. O. Int. J. Cancer 1997, 73, 50–56. (7) Brocke, C.;Kunz, H. Biorg. Med. Chem. 2002, 10, 3085–3112. (8) Toyokuni, T.; Singhal, A. K. Chem.Soc Rev. 1995, 231–242. (9) Feng, D.; Shaikh, A. S.; Wang, F. ACS Chem. Biol. 2016, 11, 850−863. (10) Slovin, S. F.; Keding, S. J.; Ragupathi, G. Immunol. Cell Biol. 2005, 83, 418–428. (11) Zhang, S.;Cordon-Cardo, C.; Zhang, H. S.; Reuter, V. E.;Adluri, S.; Hamilton, W. B.; Lloyd, K. O.; Livingston, P. O. Int. J. Cancer. 1997, 73, 42–49. (12) Livingston, P. O.; Wong, G. Y. C.; Adluri, S.; Tao, Y.;Padavan, M.; Parente, R.; Hanlon, C.; Calves, M. J.; Helling, F.; Ritter, G.; Oettgen, H. F.; Old, L. J. J. Clin. Oncol. 1994, 12, 1036–1044. (13) Cagnoni, A. J.; Pérez Sáez, J. M.; Rabinovich, G. A.; Mariño, K. V. Front. Oncol. 2016, 6, 1–21. (14) Kozlowski, E. O.; Pavao, M. S. G.; Borsig, L. J Thromb. Haemost. 2011, 9, 1807–1815. (15) Wang, R.; Huang, J.; Wei, M.; Zeng, X.; Biosci Biotechnol Biochem. 2010, 74, 1697–1700. (16) Perez-Castells, J.; Hernandez-Gay, J. J.; Denton, R. W.; Tony, K. A.; Mootoo, D. R.; Jimenez-Barbero, J. Org Biomol Chem. 2007, 5, 1087–1092. (17) Gouge-Ibert, V.; Pierry, C.; Poulain, F.; Serre, A-L.; Largeau, C.; Escriou, V. et al. Bioorg Med Chem Lett. 2010, 20, 1957–1960. (18) Bremer, E. G.; Levery, S. B.; Sonnino, S.; Ghidoni, R.; Canevari, S.; Kannagi, R.; Hakomori, S. J. Biol. Chem. 1984, 259, 14773–14777. (19) Kannagi, R.; Levery, S. B.; Ishijamik, F.; Hakomori, S.; Schevinsky, L. H.; Knowles, B. B.; Solter, D. J. Biol. Chem. 1983, 258, 8934–8942. (20) Menard, S.; Tagliabue, E.; Canevari, S.; Fossati, G.; Colnaghi, M. I. Cancer Res. 1983, 43, 1295–1300. (21) Chang, W. W.; Lee, C. H.; Lee, P.; Lin, J.; Hsu, C. W.; Hung, J. T.; Lin, J. J.; Yu, J. C.; Shao, L. E.; Yu, J.; Wong, C. H.; Yu, A. L. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11667–11672. (22) Huang, Y. L.; Hung, J. T.; Cheung, S. K. C.; Lee, H. Y.; Chu, K. C.; Li, S. T.; Lin, Y. C.; Ren, C. T.; Cheng, T. J.; Hsu, T. L.; Yu, A. L.; Wu, C. Y.; Wong, C. H. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 2517–2522. (23) Lou, Y. W.; Wang, P. Y.; Yeh, S. C.; Chuang, P. K.; Li, S. T.; Wu, C. Y.; Khoo, K. H.; Hsiao, M.; Hsu, T. L.; Wong, C.-H. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 2482–2487. (24) Bilodeau, M. T.; Park, T. K.; Hu, S.; Randolph, J. T.; Danishefsky, S. J.; Livingston, P. O.; Zhang, S. J. Am. Chem. Soc. 1995, 117, 7840–7841. (25) Danishefski, S. J.; Shue, Y. U.; Chang, M. N.; Wong, C. H. Acc. Chem. Res. 2015, 48, 643–652. (26) Lassaletta, J. M.; Schmidt, R. R. Liebigs Ann. Chem. 1996, 141. (27) Zhu, T.; Boons, G. J. Angew. Chem. Int. Ed. 1999, 38, 3495. (28) Werz, D. D.; Castagner, B.; Seeberger, P. H. J. Am. Chem. Soc. 2007, 129, 2770. (29) Allen, J. R.; Allen, J. G.; Zhang, X. F.; Williams, L. J.; Zatorski, I.; Ragupathi, G.; Livingston, P. O.; Danishefsky, S. J. Chem. Eur. J. 2000, 6, 1366–1375. (30) Wang, Z.; Zhou, L.; El-Boubbou, K.; Ye, X. S.; Huang, X. J. Org. Chem. 2007, 72, 6409–6420. (31) Jeon, I.; Iyer, K.; Danishefsky, S. J. J. Org. Chem. 2009, 74, 8452–8455. (32) Burkhart, F.; Zhang, Z.; Wacowich-Sagarbi, S.; Wong, C.-H. Angew. Chem., Int. Ed. 2001, 40, 1274–76. (33) Chang, S. H.; Han, J. L.; Tseng, S. Y.; Lee, H. Y.; Lin, C. W.; Lin, Y. C.; Jeng, W. Y.; Wang, A. H. J.; Wu, C. Y.; Wong, C.-H. J. Am. Chem. Soc. 2010, 132, 13371–13380. (34) Su, D. M.; Eguchi, H.; Yi, W.; Li, L.; Wang, P. G.; Xia, C. Org. Lett. 2008, 10, 1009–1012. (35) Tsai, T. I.; Lee, H. Y.; Chang, S. H.; Wang, C. H.; Tu, Y. C.; Lin, Y. C.; Hwang, D. R.; Wu, C. Y.; Wong, C. H. J. Am. Chem. Soc. 2013, 135, 14831–14839. (36) Huang, C. Y.; Thayer, D. A.; Chang, A. Y.; Best, M.; Hoffmann, L.; Head, S.; Wong, C. H. Proc. Natl. Acad. Sci. U.S.A. 2006, 100, 15. (37) Ragupathi, G.; Koide, F.; Livingston, P. O.; Cho, Y. S.; Endo, A.; Wan, Q.; Spassova, M. K.; Keding, S. J.; Allen, J.; Ouerfelli, O.; Wilson, R. M.; Danishefsky, S. J. J. Am. Chem. Soc 2006, 128, 2715–2725. (38) O’Cearbhaill, R. E.; Ragupathi, G.; Zhu, J.; Wan, Q.; Mironov, S.; Yang, G.; Spassova, M. K.; Iasonos, A.; Kravetz, S.; Ouerfelli, O.; Spriggs, D. R.; Danishefsky, S. J.; Sabbatini, P. J. Cancers 2016, 8, 46. (39) Zhu, J.; Wan, Q.; Lee, D.; Yang, G.; Spassova, M. K.; Ouerfelli, O.; Ragupathi, G.; Damani, P.; Livingston, P. O.; Danishefsky, S. J. J. Am. Chem. Soc. 2009, 131, 9298–9303. (40) Sabbatini, P. J.; Ragupathi, G.; Hood, C.; Aghajanian, C. A.; Juretzka, M.; Iasonos, A.; Hensley, M. L.; Spassova, M. K.; Ouerfelli, O.; Spriggs, D. R.; et al. Clin. Cancer Res. 2007, 13, 4170–4177. (41) Ragupathi, G.; Cappello, S.; Yi, S. S.; Canter, D.; Spassova, M.; Bornmann, W. G.; Danishefsky, S. J.; Livingston, P. O. Vaccine 2002, 20, 1030–1038. (42) Ragupathi, G.; Koide, F.; Sathyan, N.; Kagan, E.; Spassova, M.; Bornmann, W.; Gregor, P.; Reis, C. A.; Clausen, H.; Danishefsky, S. J.; Livingston, P. O. Cancer Immunol. Immunother. 2003, 52, 608–616. (43) Merck & Co., Inc., Pneumovax 23 (pneumococcal vaccine polyvalent). Merck website, 1986, http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf. (44) Robins, J. B.; Austrian, R.; Lee, C. J.; Rastogi, S. C.; Schiffman, G.; Henrichsen, J.; Mäkelä, P. H.; Broome, C. V.; Facklam, R. R.; Tiesjema, R. H. et al. J. Infect. Dis. 1983, 148, 1136–1159. (45) Pozsgay, V.; Chu, C.; Pannell, L.; Wolfe, J.; Robbins, J. B.; Schneerson, R. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 5194–5197. (46) Pozsgay, V.; Kubler-Kielb, J.; Schneerson, R.; Robbins, J. B.; Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 14478–14482. (47) Buskas, T.; Li, Y.; Boons, G. J.; Chem.–Eur. J. 2004, 10, 3517–3524. (48) Bhatia, S.; Dimde, M.; Haag, R. Med. Chem. Commun. 2014, 5, 862–878. (49) Akimoto, K.; Natori, T.; Morita, M. Tetrahedron Lett 1993, 34, 5593. (50) Natori, T.; Koezuka, Y.; Tatsuno, H. Tetrahedron Lett 1993, 34, 5591. (51) Godfrey, D. I.; MacDonald, H. R.; Kronenberg, M.; Smyth, M. J.; Van Kaer, L. Nat. Rev. Immunol. 2004, 4, 231–237. (52) Gonzalez-Aseguinolaza, G.; Van Kaer, L.; Bergmann, C. C.; Wilson, J. M.; Schmieg, J.; Kronenberg, M.; Nakayama, T.; Taniguchi, M.; Koewzuka, Y.; Tsuji, M. J. Exp. Med. 2002, 195, 617–624. (53) Koezuka, Y.; Kazuhiro, M.; Sakai, T.; Takenori, N. Recent Res. Dev. Cancer. 1999, 1, 341–354. (54) Brossay, L.; Chioda, M.; Burdin, N.; Kowzuka, Y.; Casorati, G.; Dellabona, P. Kronenberg, M. J. Exp. Med. 1998, 188, 1521-1528. (55) Hong, S.; Wilson, M. T.; Serizawa, I.; Wu, L.; Singh, N.; Naidenko, O. V., Miura, T.; Haba, T.; Scherer, D. C.; Wei, J. et al. Nat. Med. 2001, 7, 1052–1056. (56) Gapin, M. K. L. Nat. Rev. Immunol. 2005, 8, 557–568. (57) Singh, N.; Hong, S.; Scherer, D. C.; Serizawa, I.; Burdin, N.; Kronenberg, M,; Koezuka, Y.; Van Kaer, L. J. Immunol. 1999, 163, 2373–2377. (58) Truong, T. T.; Huynh, K.; Nakatsu, M. N.; Deng, S. X. Invest Ophthalmol Vis Sci. 2011, 52, 6315–20. (59) Gang, E. J.; Bosnakovski, D.; Figueiredo, C. A.; Visser, J. W.; Perlingeiro, R. C. Blood 2007 109, 1743–51. (60) Aloia, A.; Petrova, E.; Agorku, D.;Terranegra, A.; Mingione, A.; Judde, J. G.; Bosio, A.;Cairo, S.; Hardt. ImmunoTher. of Cancer 2015, 3, 1. (61) Brimble, S. N.; Sherrer, E. S.; Uhl, E. W.; Wang, E.; Kelly, S.; Merrill, A. H.; Robins, A. J.; Schulz, T. C. Stem Cells. 2007, 25, 54–62. (62) Thomson, J. A.; Itskovitz-Eldor, J.; Shapiro, S. S.; Waknitz, W. A.; Swiergiel, J. J.; Marshall, V. S.; Jones, J. M. Science 1998, 282, 1145–1147. (63) Slovin, S. F.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kim, S.; Spassova, M.; Bornmann, W. G.; Fazzari, M.; Dantis, L.; Olkiewicz, K.; Lloyd, K. O.; Livingston, P. O.; Danishefsky, S. J.; Scher, H. I. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 5710–5715. (64) Chang, W. W.; Lee, C. H.; Lee, P.; Lin, J.; Hsu, C. W.; Hung, J. T.; Lin, J. J.; Yu, J. C.; Shao, L. E.; Yu, J.; Wong, C. H.; Yu, A. L. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 11667–11672. (65) Wang, Z.; Zhou, L.; El-Boubbou, K.; Ye, X. H.; Huang, X. J. Org. Chem. 2007, 72, 6409–6420. (66) Pouilly, P. D.; Chenede, A.; Mallet, J. M.; Sinay, P.; Bull. Soc. Chem. Fr. 1993, 130, 256–265. (67) Burkhart, F.; Zhang, Z. Y.; Wacowich-Sgarbi, S.; Wong, C. H., Angew. Chem. Int. Ed. 2001, 40,1274–1277. (68) Zhang, Z. Y.; Ollmann, I. R.; Ye, X. S.; Wischnat, R.; Baasov, T.; Wong, C. H., J. Am. Chem. Soc. 1999, 121, 734–753. (69) Wu, X. Y.; Bundle, D. R., J. Org. Chem. 2005, 70, 7381–7388. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49137 | - |
| dc.description.abstract | Globo-H has been found expressed on cancer cells and also cancer stem cells, but not expressed in normal cells. Recently, more than 16 different types of cancers have been found Globo-H positive, including 60-65% breast cancers. Therefore, Globo-H vaccine should have highly selective and efficient toward various cancers. Moreover, scientists have found that there are SSEA3 and SSEA4 expressed on the surface of cancer cells and also cancer stem cells, and both of SSEA3 and SSEA4 are not found in normal cells. Therefore, Globo-H, SSEA3 and SSEA4 are good antigens as cancer vaccines.
There are two generations of Globo-H cancer vaccine under clinical trial. First generation of Globo-H vaccine is Globo-H-KLH vaccine, under phase III clinical trial. Second generation of Globo-H vaccine are Globo-H-DT-QS21 and Globo-H-DT-C34, under phase I clinical trial and preclinical trial respectively. First generation of Globo-H vaccine induces mainly IgM antibodies, which makes it less favorable as a vaccine. However, Globo-H-DT-C34 has been found to have significantly IgG antibodies induced, so it should be a better cancer vaccine. Further studies showed that over 98% of breast cancer patients express at least one of the three carbohydrate, Globo-H, SSEA4 and SSEA3, expressed on surface of cancer cells, so I wanted to make a divalent cancer vaccine of Globo-H and SSEA4.I used para-nitrophenol bifunctional linker to link Globo-H to DT. Afterwards, I used SBAP to attach SSEA4 to Globo-H-DT to afford Globo-H-DT-SSEA4.In another design, I tried to link Globo-H and SSEA4 to an amino acid respectively and then I will use solid phase peptide synthesis technique to control the proportion and distance of Globo-H and SSEA4. However, the following design isn’t finished yet, and I only finished the preparation of Globo-H building block. In sum, a divalent cancer vaccine of Globo-H and SSEA4 could be a new choice of carbohydrate-based cancer vaccines. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T11:17:04Z (GMT). No. of bitstreams: 1 ntu-105-R03223133-1.pdf: 13902245 bytes, checksum: bc2968b7ba10cd3a2059ac684cedec91 (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 謝誌 i
中文摘要 ii Abstract iii 目錄 iv 表目錄 vi 圖目錄 vii 流程目錄 viii 簡稱用語對照表 ix 第一章 緒論 1 第一節 腫瘤相關醣類抗原 1 第二節 Globo-H的合成 4 第三節 Globo-H抗癌疫苗的發展 10 第四節 免疫佐劑的發展 14 第五節 本篇論文目標 16 第二章 結果與討論 17 第一節 Globo-H 的化學合成 17 2-1-1. 構築體6的合成 20 2-1-2. 構築體7的合成 21 2-1-3. 構築體8的合成 23 2-1-4. 構築體9的合成 24 2-1-5. 構築體3的合成 26 2-1-6. 雙醣構築體4的合成 27 2-1-7. 三醣構築體5的合成 28 2-1-8. Globo-H的一鍋化合成 29 第二節 SSEA4 的合成 31 2-2-1. 構築體46的合成 32 2-2-2. SSEA3 (化合物49)的合成 32 2-2-3. SSEA4 (化合物48)的酵素合成 34 第三節 Globo-H與SSEA4的二價癌症疫苗合成策略一 35 2-3-1. Globo-H monoester的合成 35 2-3-2. SSEA4-SH的合成 36 2-3-3. Globo-H與SSEA4的二價癌症疫苗合成策略一 37 第四節 Globo-H與SSEA4的二價癌症疫苗合成策略二 38 2-4-1. Globo-H天冬氨酸(aspartic acid)構築體62的合成 40 第五節 結論 42 第三章 實驗部分 43 第一節 一般方法 43 第二節 化學合成與結構鑑定 44 第四章 文獻參考 67 附錄:化合物之核磁共振光譜 75 | |
| dc.language.iso | zh-TW | |
| dc.title | Globo H與SSEA4的二價癌症疫苗製備 | zh_TW |
| dc.title | Preparation of a divalent cancer vaccine of Globo H and SSEA4 | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 方俊民(Jim-Min Fang) | |
| dc.subject.keyword | 癌症疫苗,醣疫苗, | zh_TW |
| dc.subject.keyword | Globo H,SSEA4,cancer vaccine,carbohydrate-based anti-cancer vaccine, | en |
| dc.relation.page | 95 | |
| dc.identifier.doi | 10.6342/NTU201603113 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-08-20 | |
| dc.contributor.author-college | 理學院 | zh_TW |
| dc.contributor.author-dept | 化學研究所 | zh_TW |
| 顯示於系所單位： | 化學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 目前未授權公開取用 | 13.58 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。